Download PDF
Thromb Haemost 1980; 44(02): 076-080
DOI: 10.1055/s-0038-1650088
Original Article
Schattauer GmbH Stuttgart

Platelet Malondialdehyde in Cardiovascular Disease: Effect of Prosthetic Heart Valves and Cardioactive Drugs on Production

Jay M Sullivan
The Division of Cardiovascular Diseases, University of Tennessee, College of Medicine, Memphis, Tennessee, U.S.A.
,
J Charles Taylor
The Division of Cardiovascular Diseases, University of Tennessee, College of Medicine, Memphis, Tennessee, U.S.A.
,
Joseph K Samaha
The Division of Cardiovascular Diseases, University of Tennessee, College of Medicine, Memphis, Tennessee, U.S.A.
,
With the technical assistance of,
Patti Lamar
The Division of Cardiovascular Diseases, University of Tennessee, College of Medicine, Memphis, Tennessee, U.S.A.
,
Darrell R Patrick
The Division of Cardiovascular Diseases, University of Tennessee, College of Medicine, Memphis, Tennessee, U.S.A.
› Author Affiliations
Further Information

Publication History

Received 08 April 1980

Accepted 25 August 1980

Publication Date:
13 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

Malondialdehyde (MDA), a product of platelet lipid peroxidation, was measured in human platelet-rich plasma. Levels of 3.19 n moles/109 platelets ± 0.40 S.E. in 11 patients with prosthetic heart valves were elevated (p<0.25) compared to 17 normal subjects (2.09 ± 0.13 n moles/109 platelets). Reduced production (1.44 ± 0.28 n moles/109 platelets, p<0.5) was found in 10 patients with unstable angina. Normal levels were found in patients with mitral stenosis, cardiomyopathy or hypertension. Usual serum levels of drugs used in cardiac treatment reduced MDA levels as follows: acetaminophen, 47% (p<.01); aspirin, 58% (p<.05); furosemide, 32.6% (p<.005), and sulfinpyrazone, 41% (p<.05). Digoxin, dipyridamole, heparin, hydrochlorothiazide, lidocaine, nitroglycerin, procainamide, propranolol, quinidine, or warfarin had no significant effect at therapeutic concentrations. None of the drugs explained the enhanced production in patients with prosthetic valves while analgesic therapy could explain the decreased levels in other cardiacs. The half-time of platelet survival, measured by suppression of malondialdehyde production, was 3.2 ± 0.24 days in 9 normal subjects but could not be measured reliably in most patients because of multiple drug therapies. We conclude that the blood platelets of patients with prosthetic heart valves differ from those of normal subjects in their capacity to release malondialdehyde after stimulation with n-ethylmaleimide. Additionally, we find that inhibition of malondialdehyde production by several pharmacologic agents limits the usefulness of this method for the measurement of platelet survival in cardiac patients.

Key words

Blood platelets - Cardiovascular diseases - Heart valve prosthesis - Lipid peroxidation - Malondialdehyde - Prostaglandins
 

  • References

  • 1 Hamberg M, Samuelsson B. Prostaglandin endoperoxides. Novel transformations of arachidonic acid in human platelets. Proc Natl Acad Sci 1974; 71: 3400-3404
    CrossrefPubMedSearch in Google Scholar
  • 2 Hamberg M, Svensson J, Samuelsson B. Thromboxanes. A new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci 1975; 72: 2994-2998
    CrossrefPubMedSearch in Google Scholar
  • 3 Smith JB, Ingerman CM, Silver MJ. Malondialdehyde formation as an indicator of prostaglandin production by human platelets. J Lab Clin Med 1976; 88: 167-172
    PubMedSearch in Google Scholar
  • 4 Stuart MJ, Murphy S, Oski FA. A simple nonradioisotope technic for the determination of platelet life-span. N Engl J Med 1975; 292: 1310-1313
    CrossrefPubMedSearch in Google Scholar
  • 5 Harker LA, Slichter SJ. Studies of platelet and fibrinogen kinetics in patients with prosthetic heart valves. N Engl J Med 1970; 283: 1302-1305
    CrossrefPubMedSearch in Google Scholar
  • 6 Weily HS, Steele PP, Davies H, Pappas G, Genton E. Platelet survival in patients with substitute heart valves. N Engl J Med 1974; 290: 534-537
    CrossrefPubMedSearch in Google Scholar
  • 7 Okuma M, Steiner M, Baldini M. Studies on lipid peroxides in platelets. I. Method of assay and effect of storage. J Lab Clin Med 1970; 75: 283-296
    PubMedSearch in Google Scholar
  • 8 Okuma M, Steiner M, Baldini MG. Studies on lipid peroxides in platelets. II. Effect of aggregating agents and platelet antibody. J Lab Clin Med 1971; 77: 728-742
    PubMedSearch in Google Scholar
  • 9 Brecher G, Cronkite EP. Morphology and enumeration of human blood platelets. J Appl Physiol 1950; 3: 365-377
    CrossrefPubMedSearch in Google Scholar
  • 10 The Pharmacological Basis of Therapeutics Section VI. Cardiovascular Drugs. 5th. Ed. Goodman LS, Gilman A. Eds New York, Macmillan Publishing Co., Inc.: 1975: 653-752
    Search in Google Scholar
  • 11 Hamberg M, Svensson J, Samuelsson B. Prostaglandin endoperoxides. A new concept concerning the mode of action and release of prostaglandin. Proc Natl Acad Sci 1974; 71: 3824-3828
    CrossrefPubMedSearch in Google Scholar
  • 12 Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature; New Biology 1971; 231: 232-235
    CrossrefPubMedSearch in Google Scholar
  • 13 Gardner FH. Platelet kinetics and life span. Clin Haematol 1972; 1: 307-324
    PubMedSearch in Google Scholar
  • 14 Knut A, Gardner FH. Survival of blood platelets labeled with chromium. J Clin Invest 1958; 37: 1257-1268
    CrossrefPubMedSearch in Google Scholar
  • 15 Karpatkin S. Heterogeneity of human platelets. I. Metabolic and kinetic evidence suggestive of young and old platelets. J Clin Invest 1969; 48: 1073-1082
    CrossrefPubMedSearch in Google Scholar
  • 16 McDonald JW D, Ali M, Barnett WH, Nagai GR, Barnett HJ M. Effect of sulfinpyrazone on platelet release and prostaglandin synthesis. Stroke 1976; 7: 11
    PubMedSearch in Google Scholar
  • 17 Mills DC, Smith JB. The influence on platelet aggregation of drugs that effect the accumulation of adenoside 3': 5'-cyclic monophosphate in platelets. Biochem J 1971; 121: 185-196
    CrossrefPubMedSearch in Google Scholar
  • 18 Malmsten C, Granström E, Samuelsson B. Cyclic-AMP inhibits synthesis of prostaglandin endoperoxide (PGG2) in human platelets. Biochem Biophys Commun 1976; 68: 569-576
    CrossrefPubMedSearch in Google Scholar
  • 19 Moncada S, Korbut R. Dipyridamole and other phosphodiesterase inhibitors act as antithrombotic agents by potentiating endogenous prostacyclin. Lancet 1978; 1: 1286-1289
    PubMedSearch in Google Scholar
  • 20 Flower RJ, Vane JR. Inhibition of prostaglandin synthetase in brain explains the antipyretic activity of paracetomol (4-acetamidophenol). Nature 1972; 240: 410
    CrossrefPubMedSearch in Google Scholar
  • 21 Vargaftig BB, Hai ND. Inhibition of acetamidophenol of the production of prostaglandin-like material from blood platelets in vitro in relation to some in vivo actions. Eur J Pharmacol 1973; 24: 283-288
    CrossrefPubMedSearch in Google Scholar
  • 22 Mielke CH, Britten AF. Use of aspirin or acetaminophen in hemophilia. N Engl J Med 1970; 282: 1270
    CrossrefPubMedSearch in Google Scholar
  • 23 Kasper CK, Rapaport SI. Bleeding times and platelet aggregation after analgesic in hemophilia. Ann Intern Med 1972; 77: 189-193
    CrossrefPubMedSearch in Google Scholar
  • 24 Weber PC, Scherer B, Larsson C. Increase of free arachidonic acid by furosemide in man as the cause of prostaglandin and renin release. Eur J Pharmacol 1977; 41: 329-332
    CrossrefPubMedSearch in Google Scholar
  • 25 Williamson HE, Bourland WA, Marchand GR, Farley DB, Van Orden DE. Furosemide induced release of prostaglandin E to increase renal blood flow. PSEBM 1975; 150: 104-106
    PubMedSearch in Google Scholar
  • 26 Rossi EC, Levin NW. Inhibition of ADP induced platelet aggregation by furosemide. J Lab Clin Med 1973; 81: 140-147
    PubMedSearch in Google Scholar
  • 27 Ingerman CM, Smith JB, Silver MJ. Inhibition of the platelet release reaction and platelet prostaglandin synthesis by furosemide. Thromb Res 1976; 8: 417-419
    PubMedSearch in Google Scholar
  • 28 Burch JW, Stanford N, Majerus PW. Inhibition of platelet prostaglandin synthetase by oral aspirin. J Clin Invest 1978; 61: 314-319
    CrossrefPubMedSearch in Google Scholar